<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000593</url>
  </required_header>
  <id_info>
    <org_study_id>YXLL-KY-2020(040)</org_study_id>
    <nct_id>NCT05000593</nct_id>
  </id_info>
  <brief_title>Clinical Study of Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Clinical Study of Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lili Cao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qianfoshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Umbilical cord blood mononuclear cells contain hematopoietic stem cells (HSC), mesenchymal&#xD;
      stem cells (MSC), endothelial progenitor cells and other pluripotent stem cells, as well as&#xD;
      immature immune cells, which can differentiate into chondrocytes, hematopoietic, epithelial,&#xD;
      endothelial and nerve cells. It gives the ability to promote wound healing and vascular&#xD;
      microcirculation reconstruction, and has the potential to treat many diseasesHowever,&#xD;
      clinical studies on cord blood mononuclear cells in knee osteoarthritis have not been&#xD;
      reported in the literature. Therefore, this study aims to explore the safety and&#xD;
      effectiveness of cord blood mononuclear cells in the treatment of patients with knee&#xD;
      osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lysholm score</measure>
    <time_frame>Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after (third injection)</time_frame>
    <description>Evaluation of functional perception of daily activities and motor function levels of different intensities.The score ranges from 0 to 100 points, the lower the score, the more severe the knee joint damage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>American knee society knee score</measure>
    <time_frame>Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after (third injection)</time_frame>
    <description>Evaluation of the overall function and shape of the knee joint.The score ranges from 0 to 100 points. The lower the score, the worse the knee joint function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the knee injury and osteoarthritis score</measure>
    <time_frame>Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after (third injection)</time_frame>
    <description>A questionnaire for evaluating the effectiveness of knee joint injury and osteoarthropathy treatment based on patient self-assessment management.The KOOS score consists of five parts, and each part contains a different number of questions. Each question has a minimum of 0 points and a maximum of 4 points. After the score of each part is calculated separately, it is converted into a percentile score through the conversion formula. A score of 0 in the converted percentile score means that the function of that part of the joint is extremely poor, and a score of 100 means that the function of this part of the joint is completely normal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Score for pain</measure>
    <time_frame>Compare the changes of 1 month, 3 months, 6 months and one year before treatment (baseline) and after (third injection)</time_frame>
    <description>Physicians Global Assessment to measure quality of life.The score ranges from 0 to 10 points, the lower the score, the more severe the pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>stem cell treating group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-articular injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 1 week for a total of 3 times.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intra-articular injection of normal saline was performed once every 1 week for a total of 3 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Intra-articular injection of normal saline</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cord Blood Mononuclear Cells (UCB-MNCs)</intervention_name>
    <description>Intra-articular injection of Cord Blood Mononuclear Cells (UCB-MNCs)</description>
    <arm_group_label>stem cell treating group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥30 years old, ≤75 years old, no gender limit;&#xD;
&#xD;
          -  Meet the KOA diagnostic criteria in the &quot;Classification Criteria for Knee&#xD;
             Osteoarthritis&quot; revised by the American College of Rheumatology (ACR);&#xD;
&#xD;
          -  According to the X-ray K-L grading and evaluation standard, it is at level II-III;&#xD;
&#xD;
          -  Continuous pain for at least 6 months;&#xD;
&#xD;
          -  No local or systemic infection;&#xD;
&#xD;
          -  There is no obvious contraindication for articular cavity puncture in hematology and&#xD;
             biochemical testing;&#xD;
&#xD;
          -  Subjects and their families understand the clinical trial protocol and agree to&#xD;
             participate in the trial, voluntarily and sign an informed consent form;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age&lt;30 years old;&#xD;
&#xD;
          -  Tumor diseases;&#xD;
&#xD;
          -  Severe kidney, lung or liver damage;&#xD;
&#xD;
          -  Blood diseases include anemia and thrombocytopenia;&#xD;
&#xD;
          -  Type I diabetes;&#xD;
&#xD;
          -  Severe effusion;&#xD;
&#xD;
          -  Contracture or instability of the knee joint, with an axial deformity greater than&#xD;
             10°;&#xD;
&#xD;
          -  Infectious arthritis or skin disease;&#xD;
&#xD;
          -  Inject corticosteroids and immunosuppressants into the knee joint within 2 months;&#xD;
&#xD;
          -  Suffer from mental illness and poor compliance;&#xD;
&#xD;
          -  Cases that the investigator thinks are not suitable for inclusion in the group.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xinfeng Yan</last_name>
    <phone>+86 13869112527</phone>
    <email>13869112527@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Qianfoshan Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>252000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Cao</last_name>
      <email>qykyc309@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinfeng Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Diez-Perez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014 Sep;73(9):1659-64. doi: 10.1136/annrheumdis-2013-203355. Epub 2013 Jun 6.</citation>
    <PMID>23744977</PMID>
  </reference>
  <reference>
    <citation>Tang X, Wang S, Zhan S, Niu J, Tao K, Zhang Y, Lin J. The Prevalence of Symptomatic Knee Osteoarthritis in China: Results From the China Health and Retirement Longitudinal Study. Arthritis Rheumatol. 2016 Mar;68(3):648-53. doi: 10.1002/art.39465.</citation>
    <PMID>26474054</PMID>
  </reference>
  <reference>
    <citation>Wang B, Liu W, Xing D, Li R, Lv C, Li Y, Yan X, Ke Y, Xu Y, Du Y, Lin J. Injectable nanohydroxyapatite-chitosan-gelatin micro-scaffolds induce regeneration of knee subchondral bone lesions. Sci Rep. 2017 Dec 1;7(1):16709. doi: 10.1038/s41598-017-17025-6.</citation>
    <PMID>29196647</PMID>
  </reference>
  <reference>
    <citation>McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H, Kwoh K, Lohmander S, Rannou F, Roos EM, Underwood M. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.</citation>
    <PMID>24462672</PMID>
  </reference>
  <reference>
    <citation>Burke J, Hunter M, Kolhe R, Isales C, Hamrick M, Fulzele S. Therapeutic potential of mesenchymal stem cell based therapy for osteoarthritis. Clin Transl Med. 2016 Dec;5(1):27. doi: 10.1186/s40169-016-0112-7. Epub 2016 Aug 10. Review.</citation>
    <PMID>27510262</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qianfoshan Hospital</investigator_affiliation>
    <investigator_full_name>Lili Cao</investigator_full_name>
    <investigator_title>dean of orthopeadic department</investigator_title>
  </responsible_party>
  <keyword>Cord Blood Mononuclear Cells</keyword>
  <keyword>Knee Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

